Nesya Goris
Directeur/Membre du Conseil chez THERAVET SA
Profil
Dr. Nesya Goris is an Independent Director at TheraVet SA and a Chief Development Officer at ViroVet NV.
She is on the Board of Directors at TheraVet SA and Flanders Vaccine.
Dr. Goris was previously employed as a Chief Scientist by Aratana Therapeutics NV and a Director-Technical & Regulatory by AnimAb BV.
She received her graduate degree from Katholieke Universiteit Leuven and a doctorate degree from Ghent University.
Postes actifs de Nesya Goris
| Sociétés | Poste | Début |
|---|---|---|
| THERAVET SA | Directeur/Membre du Conseil | 20/12/2021 |
ViroVet NV
 ViroVet NV Pharmaceuticals: MajorHealth Technology ViroVet NV is a Belgian company that focuses on the discovery, licensing, and development of biopharmaceutical products for livestock. The company is based in Leuven, Belgium. ViroVet was founded by Erwin Blomsma, Stefaan Wera, and Nesya Goris, with Erwin Blomsma serving as the CEO since incorporation. | Fondateur | - |
| Flanders Vaccine | Directeur/Membre du Conseil | - |
Anciens postes connus de Nesya Goris
| Sociétés | Poste | Fin |
|---|---|---|
AnimAb BV
 AnimAb BV BiotechnologyHealth Technology AnimAb BV is a Belgian company that focuses on improving animal performance through its antibody-based approach that targets intestinal pathogens. AnimAb is based in Ghent, Belgium. The company helps protect piglets during their most fragile post-weaning stage. AnimAb integrates cutting-edge research, animal science, and biotechnology for product breakthroughs in animal health, cost-efficiencies, and sustainability. The company's technology prevents intestinal bacterial colonization thanks to the direct integration with animal feed. The company's cross-disciplinary science teams developed a new antibody technology designed for oral ingestion based on a scalable, cost-effective microbial production process. The company was founded in 2020 by Eric Cox, Henri de Greve, Ann Depicker, and Nico Callewaert. Alain Wille has been the CEO of the company since 2020. | Conseiller Juridique Général | - |
Aratana Therapeutics NV
 Aratana Therapeutics NV Pharmaceuticals: OtherHealth Technology Aratana Therapeutics NV engages in the development and marketing of veterinary medicine. It offers Entyce, nocita, and Galliprant. The company was founded on December 20, 2007 and is headquartered in Leuven, Belgium. | Directeur Technique/Scientifique/R&D | - |
Formation de Nesya Goris
| Ghent University | Doctorate Degree |
| Katholieke Universiteit Leuven | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| THERAVET SA | Commercial Services |
| Entreprise privées | 4 |
|---|---|
Aratana Therapeutics NV
Aratana Therapeutics NV Pharmaceuticals: OtherHealth Technology Aratana Therapeutics NV engages in the development and marketing of veterinary medicine. It offers Entyce, nocita, and Galliprant. The company was founded on December 20, 2007 and is headquartered in Leuven, Belgium. | Health Technology |
ViroVet NV
ViroVet NV Pharmaceuticals: MajorHealth Technology ViroVet NV is a Belgian company that focuses on the discovery, licensing, and development of biopharmaceutical products for livestock. The company is based in Leuven, Belgium. ViroVet was founded by Erwin Blomsma, Stefaan Wera, and Nesya Goris, with Erwin Blomsma serving as the CEO since incorporation. | Health Technology |
AnimAb BV
AnimAb BV BiotechnologyHealth Technology AnimAb BV is a Belgian company that focuses on improving animal performance through its antibody-based approach that targets intestinal pathogens. AnimAb is based in Ghent, Belgium. The company helps protect piglets during their most fragile post-weaning stage. AnimAb integrates cutting-edge research, animal science, and biotechnology for product breakthroughs in animal health, cost-efficiencies, and sustainability. The company's technology prevents intestinal bacterial colonization thanks to the direct integration with animal feed. The company's cross-disciplinary science teams developed a new antibody technology designed for oral ingestion based on a scalable, cost-effective microbial production process. The company was founded in 2020 by Eric Cox, Henri de Greve, Ann Depicker, and Nico Callewaert. Alain Wille has been the CEO of the company since 2020. | Health Technology |
| Flanders Vaccine |